Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial.
Liu X, Li Y, Li J, Zhou J, Guo J, Pu Y, Jiang Y, Zhou Y, Jiang Z, Shu Q, Wang C, Wang J, Zhao Y, Zhao W, Wang H, Wei J, Yu H, Gao J, Li X.
Liu X, et al. Among authors: wang h, wang j, wang c.
Int J Infect Dis. 2023 Sep;134:53-62. doi: 10.1016/j.ijid.2023.05.017. Epub 2023 May 19.
Int J Infect Dis. 2023.
PMID: 37211270
Free article.
Clinical Trial.